Stapled Cell-Penetrating Peptides Inhibit HIV-1 Capsid Assembly

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anti-HIV therapies face challenges due to drug resistance and the difficulty in inhibiting protein-protein interactions, particularly in the HIV-1 assembly and maturation process, where the capsid protein plays a crucial role.

Innovation Solution

Development of cell-penetrating peptides with specific sequences and unnatural amino acids, stabilized by hydrocarbon stapling, that target the capsid protein to inhibit dimerization and subsequent viral assembly and maturation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional anti-HIV drugs targeting reverse transcriptase and protease are used, then viral replication is inhibited, but drug resistance develops reducing treatment effectiveness

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddrug resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts and targets a specific critical step in the HIV life cycle - the capsid protein dimerization and assembly process - rather than using broad-spectrum antivirals that face resistance. By focusing on the capsid assembly mechanism involving the M-domain, I-domain, and L-domain, the invention develops peptides that specifically interfere with capsid formation, providing a new therapeutic approach that bypasses existing drug resistance mechanisms.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the therapeutic parameter from targeting enzymatic activities (reverse transcriptase, protease) to targeting protein-protein interactions in capsid assembly. This parameter shift involves using cell-penetrating peptides with specific sequences that bind to capsid protein domains, fundamentally altering the mechanism of action to avoid cross-resistance with traditional antiretroviral therapies.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If peptide-based drugs are developed to target HIV entry and assembly, then new therapeutic mechanisms are achieved, but cell penetration and stability become limiting factors

Engineering Contradiction:

Improvetherapeutic mechanism diversityVSAvoidcell penetration and stability

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent creates composite peptide structures by combining cell-penetrating peptide sequences with capsid-targeting sequences. The cell-penetrating domain enables membrane translocation, while the capsid-targeting domain (with specific amino acid sequences) binds to capsid protein domains. This composite structure resolves the contradiction by integrating both functions into a single molecular entity that can penetrate cells and then exert its antiviral effect.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The peptide is segmented into functional domains: a cell-penetrating segment that facilitates membrane translocation, and a capsid-targeting segment containing specific amino acid sequences that bind to capsid protein domains (M-domain, I-domain, or L-domain). This segmentation allows each domain to optimize its function while working together as an integrated therapeutic agent.

Inventive Principle:

Principle #1Segmentation

3Reliability

If proteins are used to inhibit capsid dimerization, then viral assembly is blocked, but the complexity of protein-protein interaction targeting increases difficulty

Engineering Contradiction:

Improveviral assembly inhibitionVSAvoidprotein-protein interaction targeting

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses peptides as intermediary molecules that mediate the inhibition of capsid protein dimerization. Rather than requiring direct protein-protein interaction blockade, the peptide acts as a mediator that binds to capsid protein domains (M-domain, I-domain, or L-domain) and prevents the natural dimerization process, simplifying the therapeutic approach while maintaining effectiveness.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The peptides effectively inhibit HIV-1 replication by preventing capsid dimerization and assembly, demonstrating potent antiviral activity against a wide range of HIV isolates with minimal cytotoxicity.

Implementation Method 1

wherein the two olefinic groups of the unnatural amino acids are on the same side of the a-helix and are joined to form a cross-link between the two unnatural amino acids

Methodology Applied

Scientific EffectHydrocarbon stapling: Chemical Bonding